Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00861965 · ClinicalTrials.gov registry record · Phase 1
Bioengineered Allogeneic Immune Cells (AlloStim) Not Requiring HLA Donor Match for Blood Cancers
A Phase 1 study, sponsored by Mirror Biologics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT00861965: Clinical Trial Phase 1 study, sponsored by Mirror Biologics.
NCT00861965 is a Phase 1 study that was terminated before completion, run by Mirror Biologics. The registered enrollment target is 2 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00861965, a Phase 1 study, was terminated before completion, sponsored by Mirror Biologics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
This phase I/II clinical investigation is designed to determine the safety and anti-tumor effects of intravenous administration of the experimental immunotherapy drug, called AlloStim. The active ingredient of AlloStim is living, human immune cells that have been differentiated and expanded outside the body. Because AlloStim does not require HLA match, it is being evaluated as an alternative to allogeneic bone marrow/stem cell transplantation.
Interventions
- BIOLOGICAL AlloStim-8
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2010-01 |
| Est. Completion | 2011-04 |
| Phase | Phase 1 |
Why NCT00861965 stopped before completion
NCT00861965 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which AlloStim-8 is the first listed.
NCT00861965 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00861965 about?
NCT00861965 is a clinical study titled "Bioengineered Allogeneic Immune Cells (AlloStim) Not Requiring HLA Donor Match for Blood Cancers". This phase I/II clinical investigation is designed to determine the safety and anti-tumor effects of intravenous administration of the experimental immunotherapy drug, called AlloStim. The active ingredient of AlloStim is living, human immune cells that have been differentiated and expanded outside ...
What is the current status of trial NCT00861965?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2010-01. Estimated completion is 2011-04.
What interventions are being tested in trial NCT00861965?
The interventions under investigation include: AlloStim-8 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00861965?
This trial is sponsored by Mirror Biologics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00861965's enrollment target sits among peer trials
2 2000th of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia